Results 71 to 80 of about 3,103 (173)

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025

Eurosurveillance
Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025.
Marc van der Valk
doaj   +1 more source

Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084

Journal of the International AIDS Society
Introduction Long‐acting injectable cabotegravir (CAB‐LA) for pre‐exposure prophylaxis significantly reduced HIV acquisition in HPTN 084. We report on the safety and CAB‐LA pharmacokinetics in pregnant women during the blinded period of HPTN 084. Methods
Sinead Delany‐Moretlwe, Brett Hanscom, Xu Guo, Clemensia Nkabiito, Patricia Mandima, Patricia Ntege Nahirya, Juliet Mpendo, Muchaneta Bhondai‐Mhuri, Nyaradzo Mgodi, Rebecca Berhanu, Jennifer Farrior, Estelle Piwowar‐Manning, Susan L. Ford, Craig W. Hendrix, Alex R. Rinehart, James F. Rooney, Adeola Adeyeye, Raphael J. Landovitz, Myron S. Cohen, Mina C. Hosseinipour, Mark A. Marzinke, the HPTN 084 Study Team   +21 more
doaj   +1 more source

Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations

Journal of the International AIDS Society
Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression.
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski   +23 more
doaj   +1 more source

Bridging the Gap: The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention

Viruses
Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) demonstrates superior efficacy and persistence compared to daily oral PrEP. However, real-world implementation reveals that only 52.9% of prescribed individuals initiate treatment with their ...
Adrian Charles (AC) Demidont
doaj   +1 more source

Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failure

HIV Research & Clinical Practice
Introduction In patients with severe surgical and gastrointestinal complications, standard oral combination antiretroviral therapy (ARV) may be temporarily impossible.
Krystof Sram, Hanus Rozsypal, Stanislav Sevela, Jakub Lhotan, David Jilich   +4 more
doaj   +1 more source

Optimising oral PrEP while awaiting long-acting cabotegravir

The Lancet HIV, 2023
McCormack, Sheena, Cottrell, Mackenzie Leigh   +1 more
openaire   +3 more sources

Corrigendum: Oral pre-exposure prophylaxis implementation in South Africa: a case study of USAID-supported programs

Frontiers in Reproductive Health
Jerome Wendoh Milimu, Lauren Parmley, Mahlodi Matjeng, Mathata Madibane, Mandisi Mabika, Jacques Livingston, Joseph Lawrence, Orapeleng Motlhaoleng, Hasina Subedar, Rethabile Tsekoa, Zandile Mthembu   +10 more
doaj   +3 more sources

Long-acting cabotegravir for prevention: hope versus reality [PDF]

The Lancet HIV, 2017
McCormack, S, Boffito, M
openaire   +3 more sources

Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa. [PDF]

Nat Commun
Phillips A, Smith J, Bansi-Matharu L, Sikwese K, Kityo C, Flexner C, Vitoria M, Ford N, Doherty M, Panos Z, Ripin D, Hickey M, Havlir D, Gandhi M, Reid M, Revill P.   +15 more
europepmc   +1 more source

Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP? [PDF]

J Acquir Immune Defic Syndr
D'Angelo AB, Patel VV, Carrico AW, Grov C.   +3 more
europepmc   +1 more source